Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 6/1998

01-03-1998 | ORIGINAL ARTICLE

Differential effects of all-trans-retinoic acid, docosahexaenoic acid, and hexadecylphosphocholine on cisplatin-induced cytotoxicity and apoptosis in a cisplantin-sensitive and resistant human embryonal carcinoma cell line

Authors: Hetty Timmer-Bosscha, Elisabeth G. E. de Vries, C. Meijer, J. Wolter Oosterhuis, Nanno H. Mulder

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/1998

Login to get access
Metadata
Title
Differential effects of all-trans-retinoic acid, docosahexaenoic acid, and hexadecylphosphocholine on cisplatin-induced cytotoxicity and apoptosis in a cisplantin-sensitive and resistant human embryonal carcinoma cell line
Authors
Hetty Timmer-Bosscha
Elisabeth G. E. de Vries
C. Meijer
J. Wolter Oosterhuis
Nanno H. Mulder
Publication date
01-03-1998
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 6/1998
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002800050769

Other articles of this Issue 6/1998

Cancer Chemotherapy and Pharmacology 6/1998 Go to the issue

ORIGINAL ARTICLE

Phase II trial of combination chemotherapy with cisplatin, carboplatin and etoposide in stage IIIB and IV small-cell lung cancer

ORIGINAL ARTICLE

Practical implementation of a modified continual reassessment method for dose-finding trials

SHORT COMMUNICATION

Effect of the multidrug resistance modulator valspodar on serum cortisol levels in rabbits

ORIGINAL ARTICLE

Sequence-dependent cytotoxicity of etoposide and paclitaxel in human breast and lung cancer cell lines

ORIGINAL ARTICLE

Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents

ORIGINAL ARTICLE

Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits